Randomised study of the possible adjuvant effect of BCG vaccine on the immunogenicity of diphtheria-tetanus-acellular pertussis vaccine in Senegalese infants.
Following a study in Senegal (1990-1995) in which the relative efficacy of a diphtheria-tetanus-acellular pertussis vaccine (DTaP) was compared with that of a diphtheria-tetanus-whole-cell pertussis vaccine in children given a simultaneous injection of Bacille Calmette-Guérin (BCG) vaccine, this subsequent study was conducted to evaluate the possible adjuvant effect of the BCG vaccine on acellular pertussis vaccine components. A second objective was to compare the immunogenicity of these components when administered in accordance with a 2-4-6-month (spaced) schedule or an accelerated 2-3-4-month schedule. In all, 390 healthy Senegalese infants were randomly divided into three groups of 130 infants. Antibodies to acellular pertussis components were measured in serum samples obtained within 2 days of the first DTaP dose and 1 month after the third dose. BCG vaccine, given simultaneously with the DTaP vaccine, did not influence the immunogenicity of the acellular pertussis vaccine components when compared with separate administration of the two vaccines. Infants immunised according to a 2-4-6-month schedule had a significantly higher immune response than those immunised according to a 2-3-4-month schedule with respect to the response to pertussis toxoid assessed by seroneutralisation on Chinese hamster ovary cells (P<0.0001). These results suggest that BCG and DTaP vaccines can be given simultaneously without interference or enhancement and that more optimal immunogenicity is achieved with an extended than with an accelerated schedule.
Simondon
F
F
Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Français de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Montpellier. Francois.Simondon@mpl.orstom.fr
Preziosi
M P
MP
Pinchinat
S
S
Yam
A
A
Chabirand
L
L
Wassilak
S
S
Pines
E
E
Trape
J F
JF
Salomon
H
H
Hoffenbach
A
A
D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology*; D001886:Bordetella pertussis / Q000276:immunology*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008288:Malaria / Q000276:immunology; D012675:Senegal; D014121:Toxoids / Q000276:immunology
D000907:Antibodies, Bacterial; D001500:BCG Vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D014121:Toxoids; C051093:pertussis toxoid